AIMS Charity, a leader in advancing multiple sclerosis (MS) treatment, celebrated its 5th anniversary with a landmark event in Sheffield, spotlighting the innovative StarMS treatment.
AIMS (Autoimmune and Multiple Sclerosis) Charity, renowned for its contribution to MS treatment advancements, commemorated its 5th anniversary on Saturday 25 November at Cutlers’ Hall, Sheffield. This unique event provided a platform for discussing Haematopoietic Stem Cell Transplant (HSCT) for MS, a treatment showing promising results in halting disease progression. The event featured public figures and industry experts sharing their experiences with HSCT and the pioneering StarMS treatment under trial in Sheffield and across the UK.
Distinguished attendees included documentary filmmaker Mathew Embry, makeup artist and YouTuber Nicola Chapman-Haste, BBC journalist Caroline Wyatt, and Robert Douglas-Fairhurst, a professor of English literature at Oxford.
HSCT involves chemotherapy and an autologous stem cell transplant, aiming to reset the immune system and stop MS progression. The StarMS trial compares the effectiveness and safety of Autologous Haematopoietic Stem Cell Transplantation (aHSCT) with Disease Modifying Therapies (DMTs) and investigates the mechanism of aHSCT in RRMS. This UK-wide trial involves 198 patients across 19 sites, with a 24-month follow-up including regular assessments.
The conference marked a historic milestone by gathering global HSCT experts for in-depth discussions on this revolutionary treatment’s outcomes.
Keynote speaker Dr. Richard K Burt joined other esteemed speakers, including Professor Basil Sharrack, Professor John Snowden, Dr. Majid Kazmi, Professor Gavin Giovannoni, Dr. Elisa Roldan Galvan, Dr. Guillermo Ruiz Arguelles, and Dr. Denis A Fedorenko.
Alison Coates, AIMS Charity co-founder, expressed excitement about sharing the potential of HSCT treatment. Professor Gavin Giovannon emphasised the need for neurologists to be well-versed in this transformative therapy.
HSCT, provided by Haematologists within the NHS, offers hope for halting MS progression and enhancing life quality.
AIMS Charity is dedicated to furthering MS treatment developments and providing support, aiming for a future where MS patients have access to life-changing therapies.
For more information, visit https://www.aimscharity.org/
